Better Know a Marijuana Stock: Cara Therapeutics

By:
Better Know a Marijuana Stock: Cara Therapeutics

Pixabay / TeroVesalainen / CC0 Public Domain

Cara Therapeutics is a drug developer that shares a key similarity with Insys Therapeutics: its drug development pipeline isn’t entirely devoted to cannabinoid or endocannabinoid-mimetic drugs. In fact, Cara Therapeutics, which is entirely clinical-stage at this point, is almost exclusively focused on developing CR845, a kappa opioid receptor agonist (KORA) that has nothing to do with cannabis.

Cara is angling its two experimental products in development, CR845 and CR701, at either acute or chronic pain.

View Original Article Here

Repost is the designation for articles collected from the Internet whose content may interest our readers. These articles are not written by our staff and they do not necessarily reflect our views.

Related posts

Top